Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Pharma, Inc.BBIO · Entity 3360 | CFO and Treasurer | February 25, 2025 | February 27, 2025 |
| Faeth Therapeutics, Inc.FTH · Entity 5029 | Chief Financial Officer | June 29, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Pharma, Inc.
Report date February 25, 2025 · Filed February 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 102,464 |
Ending reported balance
After 2025-02-25 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2025-02-25 · Exercise / conversion · Acquired 8,500 · Balance 110,964 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. Row 2 · 2025-02-25 · Sale · Disposed 8,400 · Balance 102,564 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. F2: Represents the weighted average sale price of the shares sold from $32.63 to $33.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Row 3 · 2025-02-25 · Sale · Disposed 100 · Balance 102,464 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2029-06-26 | Direct | 440,170 |
Reported balance
After 2025-02-25 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-25 · Exercise / conversion · Disposed 8,500 · Balance 440,170 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. F3: The shares subject to this option vested in 48 equal monthly installments from June 26, 2019 to June 26, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024.
F2: Represents the weighted average sale price of the shares sold from $32.63 to $33.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F3: The shares subject to this option vested in 48 equal monthly installments from June 26, 2019 to June 26, 2023.
Faeth Therapeutics, Inc.
Report date June 29, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 46,688 |
Last balance in matching sequence
After 2026-07-01 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rowsRow 1 · 2026-06-29 · Purchase · Acquired 831 · Balance 33,885 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.20 to $23.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Row 2 · 2026-06-30 · Purchase · Acquired 1,910 · Balance 35,795 F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.45 to $23.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Row 3 · 2026-06-30 · Purchase · Acquired 1,638 · Balance 37,433 F4: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.50 to $24.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Row 4 · 2026-06-30 · Purchase · Acquired 4,255 · Balance 41,688 F5: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.59 to $25.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Row 5 · 2026-07-01 · Purchase · Acquired 4,400 · Balance 46,088 F6: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.14 to $23.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Row 6 · 2026-07-01 · Purchase · Acquired 600 · Balance 46,688 F7: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.14 to $24.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.20 to $23.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F2: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.45 to $23.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F4: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.50 to $24.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F5: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.59 to $25.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F6: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.14 to $23.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F7: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.14 to $24.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 2, 2026 00:09 UTC | Faeth Therapeutics, Inc. FTH · Entity 5029 | PurchaseCommon Stock | 600 | $24.22 | $14,532.00 |
DisclosureSEC source: 0001780030-26-000006 · form4-07022026_120749.xml · nonDerivative · entry 6 STEPHENSON BRIAN C · CIK 0001780030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 46,688 F7 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.14 to $24.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 00:09 UTC | Faeth Therapeutics, Inc. FTH · Entity 5029 | PurchaseCommon Stock | 4,400 | $23.40 | $102,960.00 |
DisclosureSEC source: 0001780030-26-000006 · form4-07022026_120749.xml · nonDerivative · entry 5 STEPHENSON BRIAN C · CIK 0001780030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 46,088 F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.14 to $23.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 00:09 UTC | Faeth Therapeutics, Inc. FTH · Entity 5029 | PurchaseCommon Stock | 4,255 | $24.98 | $106,289.90 |
DisclosureSEC source: 0001780030-26-000006 · form4-07022026_120749.xml · nonDerivative · entry 4 STEPHENSON BRIAN C · CIK 0001780030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 41,688 F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.59 to $25.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 00:09 UTC | Faeth Therapeutics, Inc. FTH · Entity 5029 | PurchaseCommon Stock | 1,638 | $23.88 | $39,115.44 |
DisclosureSEC source: 0001780030-26-000006 · form4-07022026_120749.xml · nonDerivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 37,433 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.50 to $24.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 00:09 UTC | Faeth Therapeutics, Inc. FTH · Entity 5029 | PurchaseCommon Stock | 1,910 | $22.95 | $43,834.50 |
DisclosureSEC source: 0001780030-26-000006 · form4-07022026_120749.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 35,795 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.45 to $23.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 29, 2026 Filed Jul 2, 2026 00:09 UTC | Faeth Therapeutics, Inc. FTH · Entity 5029 | PurchaseCommon Stock | 831 | $23.34 | $19,395.54 |
DisclosureSEC source: 0001780030-26-000006 · form4-07022026_120749.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 33,885 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.20 to $23.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 26, 2026 Filed Jun 26, 2026 23:40 UTC | Faeth Therapeutics, Inc. FTH · Entity 5029 | PurchaseCommon Stock | 100 | $26.39 | $2,639.00 |
DisclosureSEC source: 0001780030-26-000005 · form4-06262026_110625.xml · nonDerivative · entry 8 STEPHENSON BRIAN C · CIK 0001780030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 33,054 F2 · ownership.nature: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 26, 2026 Filed Jun 26, 2026 23:40 UTC | Faeth Therapeutics, Inc. FTH · Entity 5029 | PurchaseCommon Stock | 1,358 | $25.55 | $34,696.90 |
DisclosureSEC source: 0001780030-26-000005 · form4-06262026_110625.xml · nonDerivative · entry 7 STEPHENSON BRIAN C · CIK 0001780030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 32,954 F7 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.335 to $26.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 26, 2026 Filed Jun 26, 2026 23:40 UTC | Faeth Therapeutics, Inc. FTH · Entity 5029 | PurchaseCommon Stock | 4,212 | $24.90 | $104,878.80 |
DisclosureSEC source: 0001780030-26-000005 · form4-06262026_110625.xml · nonDerivative · entry 6 STEPHENSON BRIAN C · CIK 0001780030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 31,596 F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.27 to $25.2405, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 26, 2026 Filed Jun 26, 2026 23:40 UTC | Faeth Therapeutics, Inc. FTH · Entity 5029 | PurchaseCommon Stock | 580 | $23.61 | $13,693.80 |
DisclosureSEC source: 0001780030-26-000005 · form4-06262026_110625.xml · nonDerivative · entry 5 STEPHENSON BRIAN C · CIK 0001780030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 27,384 F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.27 to $24.1663, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 23:40 UTC | Faeth Therapeutics, Inc. FTH · Entity 5029 | PurchaseCommon Stock | 100 | $27.77 | $2,777.00 |
DisclosureSEC source: 0001780030-26-000005 · form4-06262026_110625.xml · nonDerivative · entry 4 STEPHENSON BRIAN C · CIK 0001780030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 26,804 F2 · ownership.nature: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 23:40 UTC | Faeth Therapeutics, Inc. FTH · Entity 5029 | PurchaseCommon Stock | 3,400 | $26.98 | $91,732.00 |
DisclosureSEC source: 0001780030-26-000005 · form4-06262026_110625.xml · nonDerivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 26,704 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.61 to $27.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 23:40 UTC | Faeth Therapeutics, Inc. FTH · Entity 5029 | PurchaseCommon Stock | 3,000 | $25.98 | $77,940.00 |
DisclosureSEC source: 0001780030-26-000005 · form4-06262026_110625.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 23,304 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.58 to $26.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 23:40 UTC | Faeth Therapeutics, Inc. FTH · Entity 5029 | PurchaseCommon Stock | 2,891 | $25.22 | $72,911.02 |
DisclosureSEC source: 0001780030-26-000005 · form4-06262026_110625.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 20,304 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.50 to $25.435, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 22:58 UTC | Faeth Therapeutics, Inc. FTH · Entity 5029 | PurchaseCommon Stock | 425 | $25.91 | $11,011.75 |
DisclosureSEC source: 0001780030-26-000004 · form4-06242026_100604.xml · nonDerivative · entry 8 STEPHENSON BRIAN C · CIK 0001780030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 17,413 F9 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.64 to $26.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 22:58 UTC | Faeth Therapeutics, Inc. FTH · Entity 5029 | PurchaseCommon Stock | 1,969 | $24.84 | $48,909.96 |
DisclosureSEC source: 0001780030-26-000004 · form4-06242026_100604.xml · nonDerivative · entry 7 STEPHENSON BRIAN C · CIK 0001780030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 16,988 F8 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.64 to $25.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 22:58 UTC | Faeth Therapeutics, Inc. FTH · Entity 5029 | PurchaseCommon Stock | 6,836 | $24.12 | $164,884.32 |
DisclosureSEC source: 0001780030-26-000004 · form4-06242026_100604.xml · nonDerivative · entry 6 STEPHENSON BRIAN C · CIK 0001780030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 15,019 F7 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.62 to $24.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 22:58 UTC | Faeth Therapeutics, Inc. FTH · Entity 5029 | PurchaseCommon Stock | 356 | $23.95 | $8,526.20 |
DisclosureSEC source: 0001780030-26-000004 · form4-06242026_100604.xml · nonDerivative · entry 5 STEPHENSON BRIAN C · CIK 0001780030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 8,183 F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.82 to $24.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 22:58 UTC | Faeth Therapeutics, Inc. FTH · Entity 5029 | PurchaseCommon Stock | 3,329 | $23.28 | $77,499.12 |
DisclosureSEC source: 0001780030-26-000004 · form4-06242026_100604.xml · nonDerivative · entry 4 STEPHENSON BRIAN C · CIK 0001780030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 7,827 F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.8003 to $23.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 22:58 UTC | Faeth Therapeutics, Inc. FTH · Entity 5029 | PurchaseCommon Stock | 1,583 | $22.40 | $35,459.20 |
DisclosureSEC source: 0001780030-26-000004 · form4-06242026_100604.xml · nonDerivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 4,498 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.79 to $22.7733, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 22:58 UTC | Faeth Therapeutics, Inc. FTH · Entity 5029 | PurchaseCommon Stock | 1,118 | $20.82 | $23,276.76 |
DisclosureSEC source: 0001780030-26-000004 · form4-06242026_100604.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,915 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.62 to $21.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 22:58 UTC | Faeth Therapeutics, Inc. FTH · Entity 5029 | PurchaseCommon Stock | 1,797 | $20.23 | $36,353.31 |
DisclosureSEC source: 0001780030-26-000004 · form4-06242026_100604.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,797 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.5765 to $20.545, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 22:36 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (right to buy) · Derivative | 8,500 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000950170-25-029262 · ownership.xml · derivative · entry 4 STEPHENSON BRIAN C · CIK 0001780030 · CFO and Treasurer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 440,170 Underlying: Common Stock · 8,500 shares Expires 2029-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. F3 · derivative.exercise_date: The shares subject to this option vested in 48 equal monthly installments from June 26, 2019 to June 26, 2023. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 22:36 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 100 | $34.18 | $3,418.00 |
DisclosureSEC source: 0000950170-25-029262 · ownership.xml · nonDerivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · CFO and Treasurer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,464 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 22:36 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 8,400 | $33.18 | $278,696.88 |
DisclosureSEC source: 0000950170-25-029262 · ownership.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · CFO and Treasurer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,564 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. F2 · price: Represents the weighted average sale price of the shares sold from $32.63 to $33.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 22:36 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 8,500 | $17.00 | $144,500.00 |
DisclosureSEC source: 0000950170-25-029262 · ownership.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · CFO and Treasurer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 01:50 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 4,148 | $36.16 | $149,973.43 |
DisclosureSEC source: 0000950170-25-023630 · ownership.xml · nonDerivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,464 F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. F5 · price: Represents the weighted average sale price of the shares sold from $35.57 to $36.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 01:50 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 6,705 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-023630 · ownership.xml · derivative · entry 7 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,459 Underlying: Common Stock · 6,705 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F9 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F9 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 01:50 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 17,368 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-023630 · ownership.xml · derivative · entry 6 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,947 Underlying: Common Stock · 17,368 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F8 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F8 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 01:50 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 946 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-023630 · ownership.xml · derivative · entry 5 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,840 Underlying: Common Stock · 946 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F7 · derivative.exercise_date: The RSUs vested with respect to 25% of the underlying shares on November 16, 2022. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F7 · derivative.expiration_date: The RSUs vested with respect to 25% of the underlying shares on November 16, 2022. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 01:50 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 779 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-023630 · ownership.xml · derivative · entry 4 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 779 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2021. Thereafter, 1/16th of the underlying shares vested on a quarterly basis. The RSUs have no expiration date. F6 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2021. Thereafter, 1/16th of the underlying shares vested on a quarterly basis. The RSUs have no expiration date. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 01:50 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 13,102 | $34.90 | $457,259.80 |
DisclosureSEC source: 0000950170-25-023630 · ownership.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,612 F3 · shares: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax obligation in connection with the vesting of 25,798 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 01:50 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 25,798 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-023630 · ownership.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,714 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · balance_after: Includes 158 shares of the Issuer's Common Stock acquired by the Reporting Person on February 14, 2025 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| January 28, 2025 Filed Jan 30, 2025 23:31 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (right to buy) · Derivative | 68,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000950170-25-011242 · ownership.xml · derivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 448,670 Underlying: Common Stock · 68,000 shares Expires 2029-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to this option vested in 48 equal monthly installments from June 26, 2019 to June 26, 2023. Read SEC document |
| January 28, 2025 Filed Jan 30, 2025 23:31 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 68,000 | $36.29 | $2,467,760.80 |
DisclosureSEC source: 0000950170-25-011242 · ownership.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,758 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. F2 · price: Represents the weighted average sale price of the shares sold from $35.75 to $36.71 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| January 28, 2025 Filed Jan 30, 2025 23:31 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 68,000 | $17.00 | $1,156,000.00 |
DisclosureSEC source: 0000950170-25-011242 · ownership.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2024 Filed Dec 13, 2024 00:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantRestricted Stock Units · Derivative | 42,683 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-135983 · ownership.xml · derivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,683 Underlying: Common Stock · 42,683 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vest with respect to 1/2 of the underlying shares on December 12, 2025. Thereafter, the remaining underlying shares shall vest on December 12, 2026, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F2 · derivative.expiration_date: The RSUs vest with respect to 1/2 of the underlying shares on December 12, 2025. Thereafter, the remaining underlying shares shall vest on December 12, 2026, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| November 19, 2024 Filed Nov 21, 2024 00:57 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 4,156 | $22.41 | $93,136.79 |
DisclosureSEC source: 0000950170-24-129452 · ownership.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,758 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. F2 · price: Represents the weighted average sale price of the shares sold ranging from $21.95 to $22.78 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| November 16, 2024 Filed Nov 19, 2024 23:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 6,705 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-128888 · ownership.xml · derivative · entry 6 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,164 Underlying: Common Stock · 6,705 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F6 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| November 16, 2024 Filed Nov 19, 2024 23:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 17,369 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-128888 · ownership.xml · derivative · entry 5 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,315 Underlying: Common Stock · 17,369 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F5 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| November 16, 2024 Filed Nov 19, 2024 23:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 947 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-128888 · ownership.xml · derivative · entry 4 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,786 Underlying: Common Stock · 947 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vested with respect to 25% of the underlying shares on November 16, 2022. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F4 · derivative.expiration_date: The RSUs vested with respect to 25% of the underlying shares on November 16, 2022. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| November 16, 2024 Filed Nov 19, 2024 23:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 778 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-128888 · ownership.xml · derivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 779 Underlying: Common Stock · 778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2021. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F3 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2021. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| November 16, 2024 Filed Nov 19, 2024 23:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 13,077 | $23.72 | $310,186.44 |
DisclosureSEC source: 0000950170-24-128888 · ownership.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,914 F2 · shares: Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 25,799 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| November 16, 2024 Filed Nov 19, 2024 23:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 25,799 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-128888 · ownership.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 22:27 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 1,698 | $25.13 | $42,668.70 |
DisclosureSEC source: 0000950170-24-099269 · ownership.xml · nonDerivative · entry 4 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,192 F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. F6 · price: Represents the weighted average sale price of the shares sold ranging from $24.91 to $25.17 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 22:27 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 2,457 | $24.39 | $59,920.82 |
DisclosureSEC source: 0000950170-24-099269 · ownership.xml · nonDerivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,890 F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. F5 · price: Represents the weighted average sale price of the shares sold ranging from $23.91 to $24.90 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 22:27 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 6,705 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-099269 · ownership.xml · derivative · entry 8 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,869 Underlying: Common Stock · 6,705 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F10 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F10 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 22:27 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 17,368 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-099269 · ownership.xml · derivative · entry 7 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,684 Underlying: Common Stock · 17,368 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F9 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F9 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 22:27 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 946 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-099269 · ownership.xml · derivative · entry 6 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,733 Underlying: Common Stock · 946 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F8 · derivative.exercise_date: The RSUs vested with respect to 25% of the underlying shares on November 16, 2022. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F8 · derivative.expiration_date: The RSUs vested with respect to 25% of the underlying shares on November 16, 2022. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 22:27 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 778 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-099269 · ownership.xml · derivative · entry 5 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,557 Underlying: Common Stock · 778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F7 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2021. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F7 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2021. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.